This workflow is for UK medical oncology trainees preparing for the SCE who are tempted to lean on ESMO examination materials — and the first thing to say is a coverage warning, not a study tip. The ESMO Examination for Medical Oncologists is a separate European assessment, built on the ESMO/ASCO Global Curriculum and ESMO Clinical Practice Guidelines, and it is not the UK SCE. Its resources are excellent oncology learning material, but they are calibrated to a different exam and a partly different evidence base. Use them for knowledge breadth if you like, but calibrate to the exam you are actually sitting using the Federation of Royal Colleges of Physicians' official SCE Medical Oncology sample, not ESMO items.
Current-state box: what "ESMO Examination Resources" are, and are not
Last checked 21 July 2026. ESMO (esmo.org) runs the ESMO Examination for Medical Oncologists, a knowledge assessment described as a benchmark for practising and training oncologists and used as part of national board certification in some European countries. It is anchored to the ESMO/ASCO Global Curriculum and ESMO guidelines; verify its current format, timing and eligibility on esmo.org, as those details are not reproduced reliably outside the member portal. Third-party ESMO-exam banks exist and are vendor-reported — for example, one specialist provider lists a separate ESMO oncology bank distinct from its UK SCE bank — but none of these are the UK SCE's official questions. The key point for a UK candidate: ESMO materials are for a European exam; the UK SCE's official released items come from the Federation. Do not treat one as a substitute for the other.
Exam anchor: the UK SCE Medical Oncology format and blueprint
The SCE in Medical Oncology is delivered by the Federation as two papers of 100 best-of-five questions — 200 in total — each paper three hours, on one day, at a Surpass computer-based test centre, one mark per correct answer, no negative marking. The pass mark is benchmarked against the standard of UK trainees completing training and moves slightly with difficulty. The blueprint spans site-specific tumours — breast, lung and thoracic, colorectal and upper gastrointestinal, genitourinary, gynaecological, head and neck, central nervous system, skin, sarcoma, lymphoma and carcinoma of unknown primary — and non-site-specific themes: acute oncology and oncological emergencies, systemic anti-cancer therapy including immunotherapy and its toxicity, radiotherapy principles, supportive and palliative care, cancer genetics, screening and prevention, and clinical trials, statistics and research governance. The official requirement is UK practice; that is where ESMO material diverges.
Why ESMO items need translating for a UK exam
The most important difference is the evidence base. ESMO guidance reflects European approvals and the ESMO-Magnitude of Clinical Benefit Scale; the UK SCE reflects UK practice and commissioning — NICE technology appraisals, the Cancer Drugs Fund, SACT protocols and NHS acute-oncology pathways. A regimen that is standard in an ESMO guideline may not be commissioned in the UK, and vice versa, and the SCE expects the UK position. So an ESMO question is not "wrong", but its answer may not be the UK best answer. Treat ESMO resources as content to translate, always checking the UK stance from NICE, the SmPC via the electronic medicines compendium, and UK acute-oncology guidance before you commit an answer to memory.
Inventory the material and label each item
Inventory everything and label each item by exposure: unseen, attempted once, or contaminated by review. Your scarcest and most valuable resource is the Federation's official SCE Medical Oncology sample and online practice test — keep these unseen for as long as possible, because they are the closest proxy to the real paper and there is a finite supply. ESMO learning materials and any ESMO-exam bank are learning content: useful, but not your calibration standard, so it does not matter as much if you review them repeatedly. Labelling matters because it stops you spending your one clean UK benchmark on a casual read-through months out.
Choose the calibration date
Fix a calibration date four to six weeks before the exam — late enough to be meaningful, early enough to act on. On that day you sit the Federation's official UK sample under exam conditions. Choosing the date in advance protects the official material from being frittered away and guarantees you a clean, UK-specific benchmark at the point in your revision when you can still change course.
Reproduce exam conditions exactly
Reproduce the UK exam precisely on calibration day: best-of-five items, roughly 1.8 minutes each, no references open, the same breaks you will get on the day, and the discipline of committing to a single best answer with flags for review rather than leaving blanks. Because there is no negative marking, always answer. A calibration done with guidelines open measures your literature-search skill, not your recall — and on the day you will have neither the ESMO app nor NICE open beside you. Rehearse the Surpass interface as well: navigating between items, flagging a question and returning to it should be automatic before exam day, so the only thing you are testing on the day is your oncology and your UK judgement, not your familiarity with the software under a running clock.
Code every error, not just the subject
Code each miss three ways: by domain (which blueprint area), by cognitive process (knowledge gap, misread stem, calculation error, or faulty next-step prioritisation), and by format (staging, a biomarker-driven decision, an image or radiograph, a toxicity-grading item, a statistics stem). In oncology, add a fourth tag your ESMO practice makes essential: jurisdiction — was the miss because you gave the European answer where the UK commissions differently? A cluster of jurisdiction errors is a signal to re-anchor on NICE and UK pathways, not to do more ESMO questions.
Map each error to fresh practice, and protect the official items
Turn each coded error into a fresh action: a spaced set of new questions in the weak tumour site or theme, a focused read of the relevant UK guidance, or a translation note where ESMO and UK practice diverge. Keep the Federation's official questions out of daily repetition so they remain a clean benchmark; your day-to-day volume should come from a UK SCE bank and unseen transfer questions. Re-run the official sample only when a genuinely new one is released — otherwise re-measure with unseen items so you are testing recall, not memory of the benchmark.
Worked example: a seven-day plan around clinical work
A realistic week for a trainee revising around oncology service, using ESMO resources for one defined job — building conceptual understanding of tumour biology and systemic therapy — and iatroX for unseen UK-level transfer measurement. No proprietary-algorithm claims; the mechanism is ordinary spaced, mixed retrieval.
- Monday: Study one ESMO guideline summary on a weak site (say, immunotherapy toxicity). Write a one-line UK-translation note for each key recommendation (does NICE commission this?). 35 minutes.
- Tuesday: Timed 30-question UK SCE-bank block on that site; code every error by domain, process, format and jurisdiction. 45 minutes.
- Wednesday: Spaced retrieval of the week's misses, plus a carboplatin AUC (Calvert) and creatinine-clearance calculation drill. 25 minutes.
- Thursday: Fresh, timed, unseen mixed block in iatroX; record first-attempt accuracy to measure transfer. 30 minutes.
- Friday: Second ESMO resource on a different theme (say, clinical-trial endpoints); write UK-translation notes. 30 minutes.
- Saturday: Longer 50-question timed mixed block for stamina; log high-confidence and jurisdiction errors separately. 75 minutes.
- Sunday: Review error codes, update the coverage table, plan next week. Rest otherwise.
Every four to six weeks, swap one session for a Federation official-sample calibration under full conditions.
Decision checklist: continue, supplement, switch or stop
Use measured gaps, not novelty or sunk cost. Continue with ESMO resources for learning while your coverage table shows genuine knowledge gaps and you are disciplined about UK translation. Supplement with a dedicated UK SCE bank (StudyPRN publishes one; Licence Medical lists one) the moment you notice jurisdiction errors — that is the gap ESMO material cannot close. Add iatroX as the unseen-measurement layer once your recognition is high but transfer lags. Switch your primary practice source if your errors are dominated by out-of-date or non-UK content. Stop adding new material when your unseen UK mixed score is comfortably above the standard, your official-sample calibration is clean, and your remaining errors are careless rather than knowledge gaps.
Reading your calibration result
When you sit the Federation's official sample, do not convert the score into a pass prediction. The set is small, so one score carries a wide margin and cannot forecast a 200-item paper. Read it directionally instead: which tumour sites fell below your bank accuracy; how many of your misses were jurisdiction errors, where you gave the European rather than the UK-commissioned answer; whether your pacing held at roughly 1.8 minutes per item; and whether your confident answers were reliable. A candidate whose oncology knowledge is sound but whose misses are mostly jurisdiction errors has a translation problem, not a knowledge problem, and the fix is re-anchoring on NICE and UK pathways rather than doing more content. Reading the result this way turns a number into a plan, and it works only because you calibrated early enough to act on it.
Three mistakes this workflow is designed to stop
The first mistake is treating ESMO materials as calibration for the UK SCE. The ESMO Examination is a different exam with its own curriculum and pass standard, so an ESMO practice score tells you little about your readiness for the Federation's paper. Calibrate against the Federation's official UK sample, and use ESMO content only as learning material to be translated.
The second mistake is importing European best answers into a UK exam without translation. ESMO guidance reflects European approvals and the ESMO-Magnitude of Clinical Benefit Scale; the UK SCE expects the NICE-commissioned, NHS-standard answer. A regimen that is first-line in an ESMO guideline may not be funded in the UK, and choosing it in the exam is a confident wrong answer. Every ESMO recommendation you revise should carry a one-line note on whether UK practice agrees.
The third mistake is leaving the Federation's official sample until the final week. Because it is your only clean UK benchmark, sitting it too late means you discover your jurisdiction and pacing problems when there is no time to fix them. Fix the calibration date four to six weeks out, keep the official material unseen until then, and give yourself room to act on what it shows.
Bottom line
ESMO resources are excellent oncology learning material for a different, European exam. For the UK SCE they are content to translate, not a calibration standard. Build coverage from a UK SCE bank, translate every ESMO recommendation into its UK position, calibrate against the Federation's official sample under exam conditions, and use an unseen cross-specialty bank such as iatroX to confirm transfer. Learn, translate, calibrate, measure — in that order — and the European material becomes an asset rather than a trap.
Frequently asked questions
Is ESMO Examination Resources enough for SCE Medical Oncology on its own? No. ESMO materials are built for the ESMO Examination, a separate European exam with a partly different evidence base, so on their own they will leave you exposed on UK-specific practice — NICE commissioning, the Cancer Drugs Fund, SACT protocols and UK acute-oncology pathways. They are strong learning content, but for the UK SCE you need a UK-oriented question bank for volume and the Federation's official sample for calibration. Used as your only resource, ESMO material risks teaching you the right oncology and the wrong best answer for this exam.
Which SCE Medical Oncology component does ESMO Examination Resources not reproduce well? It under-reproduces the UK-jurisdiction dimension and the exam's specific best-of-five format at UK pace. ESMO questions may frame decisions around European approvals and ESMO-MCBS rather than NICE appraisals, and they are calibrated to a different pass standard. The UK-practice best-answer judgement — knowing what is commissioned and standard in the NHS — is reproduced by a UK SCE bank and the Federation's official sample, not by ESMO material.
How many ESMO Examination Resources questions should I complete per day for SCE Medical Oncology? Rather than chase a daily ESMO count, cap ESMO work at the learning role — perhaps one guideline summary or a short question set per study day, always with UK-translation notes — and put your countable daily volume through a UK SCE bank, aiming for a sustainable timed block of 30 to 40 questions with full error-coding. The measure that matters is not how many ESMO items you did but whether your UK-translated knowledge transfers to unseen UK questions.
When should I stop using ESMO Examination Resources and move to mixed mocks? Move the centre of gravity to full-length UK mixed mocks in the final three to four weeks, once your tumour-site knowledge is adequate and your outstanding needs are pacing, stamina and UK best-answer discipline. Keep ESMO resources only for patching specific conceptual gaps the mocks reveal; do not let a European exam's materials dominate your final UK-exam rehearsal.
How should I combine ESMO Examination Resources with iatroX without duplicating practice? Assign clear roles: ESMO material for conceptual oncology learning, a UK SCE bank for exam-style volume, and iatroX as the unseen cross-specialty UK measurement layer that checks whether your knowledge transfers. Because iatroX is not a specialty oncology SCE bank but a broad UK MRCP-level bank, its items will not duplicate either ESMO content or a specialty SCE bank — which is exactly why it works as a clean second measurement, in line with the two-Q-bank rule.
Editorial notes and references
Written by Dr Kolawole Tytler, NHS GP and founder of iatroX. Last checked 21 July 2026. Coverage note and honesty flag: the ESMO Examination is a distinct European assessment based on the ESMO/ASCO Global Curriculum and ESMO guidelines, not the UK MRCP(UK) SCE; UK candidates should calibrate against the Federation of Royal Colleges of Physicians' official SCE Medical Oncology sample rather than ESMO items. Verify ESMO's current exam format on esmo.org. Third-party question counts and prices in this series are vendor-reported and change without notice; verify on the product page. Disclosure: iatroX operates a UK question bank and competes with specialty SCE banks; its role here is confined to unseen measurement and cross-specialty knowledge. Corrections via the feedback route on iatrox.com.
References: ESMO — Examination for Medical Oncologists; Federation of Royal Colleges of Physicians — SCE in Medical Oncology; iatroX — why a Q-bank percentage is not your exam score and the SCE Medical Oncology content-gap checklist.